ImpediMed

ImpediMed Capital Intensity

The Capital Intensity Ratio of ImpediMed (IPD.AX) as of Nov 11, 2026 is 237.19 %. In the previous year, Capital Intensity Ratio was 327.41 % — a change of -27.56% (lower).

Capital Intensity

237.19 %

YoY

-27.56%

Last updated:

Capital Intensity Ratio of ImpediMed is 2026 237.19 % . Capital Intensity Ratio of ImpediMed was 2025 327.41 % . It decreases by -27.56% lower compared to the previous year.

The ImpediMed Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2019
543.33 AUD
Jan 1, 2020
575.93 AUD
Jan 1, 2021
406.77 AUD
Jan 1, 2022
555.55 AUD
Jan 1, 2023
605.92 AUD
Jan 1, 2024
455.33 AUD
Jan 1, 2025
327.41 AUD
Jan 1, 2026
237.19 AUD
The ImpediMed Capital Intensity history
YEARCapital IntensityYoY
237.19 %-27.56%
327.41 %-28.09%
455.33 %-24.85%
605.92 %+9.07%
555.55 %+36.58%
406.77 %-29.37%
575.93 %+6.00%
543.33 %-56.63%
1,252.83 %+12.27%
1,115.90 %-28.65%
1,563.98 %+99.80%
782.76 %+84.26%
424.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Capital Intensity Ratio of ImpediMed is 237.19 % in 2026.

Capital Intensity Ratio of ImpediMed changed from 327.41 % to 237.19 %, representing a -27.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's ImpediMed with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ImpediMed

All Key Metrics — ImpediMed